Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health www.cancer.gov

Navigation

Personal tools

You are here: Home / Biomarkers / FAS

FAS

Basics

Aliases:
This biomarker is also known as:
  • FAS 827dupA,
  • TNFRSF6,
  • apoptosis antigen 1,
  • APO-1,
  • APT1,
  • Apo-1 antigen,
  • Fas AMA,
  • FAS (Ab2),
  • tumor necrosis factor receptor superfamily, member 6,
  • ALPS1A,
  • apoptosis-mediating surface antigen FAS,
  • Apoptosis-mediating surface antigen FAS,
  • FAS (Ab1),
  • Delta Fas/APO-1/CD95,
  • CD95,
  • FASLG receptor,
  • FASTM,
  • tumor necrosis factor receptor superfamily member 6,
  • Fas (TNF receptor superfamily, member 6),
  • APO-1 cell surface antigen,
  • FAS1,
  • CD95 antigen,

View in BioMuta

Description…

FAS is a member of the TNF-receptor superfamily. The FAS protein is a receptor for TNFSF6/FASLG and has been shown to play a central role in the physiological regulation of programmed cell death, and has been implicated in the pathogenesis of various malignancies and diseases of the immune system. Several alternatively spliced transcript variants have been described, some of which are candidates for nonsense-mediated mRNA decay (NMD). The isoforms lacking the transmembrane domain may negatively regulate the apoptosis mediated by the full length isoform.

Attributes

QA State: Curated
Type: Protein
Short Name:
HGNC Name: FAS

Datasets

There are no datasets associated with this biomarker.

Organs

The following organs have data associated with this biomarker…

Breast

Attributes

Phase: Two
QA State: Under Review

Overview

No additional breast data available.

Performance Comment

FAS was one of numerous potential early detection biomarkers specific to triple-negative breast cancer in multiple pathways identified.

Ovary

Attributes

Phase: Three
QA State: Under Review

Overview

APO-1/Fas receptor (FasR) is a cell surface receptor that, when activated, triggers apoptosis. It has been postulated that this receptor may be involved in the clearance of benign ovarian epithelial inclusion cysts (IC). An observed decreased expression of FasR in malignant ovarian epithelial neoplasms as compared with benign ovarian epithelial lesions suggests that a decreased sensitivity to Fas-mediated apoptosis may be involved in ovarian epithelial carcinogenesis.

Performance Comment

Studies

This biomarker is currently being annotated or is under review. You must be logged in or do not have permission to view any additional information. Contact Heather Kincaid at heather.kincaid@jpl.nasa.gov if you should have access to this biomarker.

2015 EDRN PI Orientation

The New and Continuing EDRN Principal Investigator Orientation will take place October 15–16, 2015 in Bethesda, Maryland.

Announcement 06/30/2015

A funding opportunity for a new pancreatic cancer initiative, called The Pancreatic Cancer Detection Consortium (U01), has been released. For more information, please go to http://grants.nih.gov /grants/guide/ pa-files/ PAR-15-289.html.

Announcement 04/08/2015

Thank you to everyone who made the 29th EDRN Steering Committee Meeting a success. The orientation for new and continuing EDRN PIs will be held October 15-16, 2015 on the NCI campus. More information will be available later this summer.